Abstract:An in situ hydrogel vaccine is fabricated by co‐encapsulating Fms‐like tyrosine kinase 3 ligand (FLT3L), Poly I:C, and Nap‐Ce6/UCM (NCUM). Ce6 triggered Photodynamic therapy (PDT) induces tumor antigens release in situ. cDC1 is recruited to tumor tissue and activated for cross‐presentation, followed by migrating to lymph nodes and activating CTLs. Tumor stemness is inhibited by napabucasin, which helps CTLs to achieve comprehensive tumor killing. Effective presentation of antigens by dendritic cells (DC) is essential for achieving a robust cytotoxic T lymphocytes (CTLs) response, in which cDC1 is the key DC subtype for high‐performance activation of CTLs. However, low cDC1 proportion, complex process, and high cost severely hindered cDC1 generation and application. Herein, the study proposes an in situ cDC1 recruitment and activation strategy with simultaneous inhibiting cancer stemness for inducing robust CTL responses and enhancing the anti‐tumor effect. Fms‐like tyrosine kinase 3 ligand (FLT3L), Poly I:C, and Nap‐CUM (NCUM), playing the role of cDC1 recruitment, cDC1 activation, inducing antigen release and decreasing tumor cell stemness, respectively, are co‐encapsulated in an in situ hydrogel vaccine (FP/NCUM‐Gel). FP/NCUM‐Gel is gelated in situ after intra‐tumoral injection. With the near‐infrared irradiation, tumor cell immunogenic cell death occurred, tumor antigens and immunogenic signals are released in situ. cDC1 is recruited to tumor tissue and activated for antigen cross‐presentation, followed by migrating to lymph nodes and activating CTLs. Furthermore, tumor cell stemness are inhibited by napabucasin, which can help CTLs to achieve comprehensive tumor killing. Collectively, the proposed strategy of cDC1 in situ recruitment and activation combined with stemness inhibition provides great immune response and anti‐tumor potential, providing new ideas for clinical tumor vaccine design.

Fucoidan based Ce6-chloroquine self-assembled hydrogel as in situ vaccines to enhance tumor immunotherapy by autophagy inhibition and macrophage polarization

Quantum Dot-Pulsed Dendritic Cell Vaccines Plus Macrophage Polarization for Amplified Cancer Immunotherapy.

In Situ Hydrogel Modulates cDC1‐Based Antigen Presentation and Cancer Stemness to Enhance Cancer Vaccine Efficiency

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

Bis-2'-F-cGSASMP isomers encapsulated in cytidinyl/cationic lipids act as potent in situ autologous tumor vaccines

EISA in Tandem with ICD to form in Situ Nanofiber Vaccine for Enhanced Tumor Radioimmunotherapy

Bifunctional Fusion Membrane‐Based Hydrogel Enhances Antitumor Potency of Autologous Cancer Vaccines by Activating Dendritic Cells

Programming of in Situ Tumor Vaccines via Supramolecular Nanodrug/Hydrogel Composite and Deformable Nanoadjuvant for Cancer Immunotherapy

Fused Cytomembrane‐Camouflaged Nanoparticles for Tumor‐Specific Immunotherapy

Carrageenan-ferrocene-eicosapentaenoic acid composite hydrogel induce ferroptosis and apoptosis for anti-tumor recurrence and metastasis

In Situ Vaccination with An Injectable Nucleic Acid Hydrogel for Synergistic Cancer Immunotherapy

Allogenic Dendritic Cell and Tumor Cell Fused Vaccine for Targeted Imaging and Enhanced Immunotherapeutic Efficacy of Gastric Cancer.

Photodynamic Therapy Combined with Antihypoxic Signaling and CpG Adjuvant as an In Situ Tumor Vaccine Based on Metal–Organic Framework Nanoparticles to Boost Cancer Immunotherapy

Polydopamine nanoparticles cross-linked hyaluronic acid photothermal hydrogel with cascading immunoinducible effects for in situ antitumor vaccination

Self-assembly Nanoparticles Potentiate In-Situ Tumor Vaccine of Radiotherapy by Regulating Tumor Immunogenicity and Tumor-Associated Macrophages

Fluorocarbon Modified Chitosan to Enable Transdermal Immunotherapy for Melanoma Treatment

Cascade Carrier‐Free Nanoparticles Forming In Situ Nanovaccines for Synergistic Photothermal‐Immunotherapy of Cancer

Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy

Metal-Organic Framework-Based Nanovaccine for Relieving Immunosuppressive Tumors Via Hindering Efferocytosis of Macrophages and Promoting Pyroptosis and Cuproptosis of Cancer Cells.

Supramolecular Tadalafil Nanovaccine for Cancer Immunotherapy by Alleviating Myeloid-Derived Suppressor Cells and Heightening Immunogenicity

Chitosan-based nano-micelles for potential anti-tumor immunotherapy: Synergistic effect of cGAS-STING signaling pathway activation and tumor antigen absorption